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Colorectal tumorigenesis is driven by genetic alterations in the
adenomatous polyposis coli (APC) tumor suppressor pathway and
effectively inhibited by nonsteroidal antiinflammatory drugs
(NSAIDs). However, how NSAIDs prevent colorectal tumorigenesis
has remained obscure. We found that the extrinsic apoptotic path-
way and the BH3 interacting-domain death agonist (BID) are acti-
vated in adenomas from NSAID-treated patients. Loss of BID
abolishes NSAID-mediated tumor suppression, survival benefit,
and apoptosis in tumor-initiating stem cells in APCMin/+ mice.
BID-mediated cross-talk between the extrinsic and intrinsic apo-
ptotic pathways is responsible for selective killing of neoplastic
cells by NSAIDs. We further demonstrate that NSAIDs induce death
receptor signaling in both cancer and normal cells, but only acti-
vate BID in cells with APC deficiency and ensuing c-Myc activation.
Our results suggest that NSAIDs suppress intestinal tumorigenesis
through BID-mediated synthetic lethality triggered by death re-
ceptor signaling and gatekeeper mutations, and provide a ratio-
nale for developing more effective cancer prevention strategies
and agents.
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Colorectal cancer (CRC) is the third leading cause of cancer-related death in the United States (1). However, treatment
options for advanced colorectal cancer, including radiation, cy-
totoxic, and targeted therapies, are of limited effectiveness.
Colorectal tumorigenesis is driven by genetic alterations in the
APC tumor suppressor pathway through aberrant Wnt signaling,
leading to β-catenin accumulation and activation of oncogenes
such as c-Myc and CCND1 (2). One of the most promising
strategies for reducing the morbidity and mortality of CRC is to
inhibit tumorigenesis by using natural products or pharmacologic
agents, such as nonsteroidal antiinflammatory drugs (NSAIDs)
(3). The chemopreventive activities of NSAIDs, such as aspirin
and sulindac, have been demonstrated in epidemiological studies
(4), clinical trials (5, 6), and animal models (7). However, the
critical cellular activities and molecular targets of NSAIDs in
chemoprevention have remained elusive.
It is suggested that the antitumor effects of NSAIDs require
selective killing of neoplastic cells through apoptosis (8), a major
turnover mechanism of intestinal epithelial cells (9). Apoptotic
death is regulated by the death receptor (DR or extrinsic) and
mitochondrial (intrinsic) pathways (10). The DR pathway
involves activation of death receptors such as DR4 and DR5,
recruitment of FADD and procaspase 8, and depletion of pro-
survival proteins such as c-FLIP, resulting in activation of the
recruited caspase 8 and other caspases (11). The mitochondrial
pathway is regulated by the Bcl-2 family proteins (12) and
characterized by mitochondrial dysfunction, release of cyto-
chrome c, and activation of caspase 9 (10). These two pathways
cross talk under certain conditions through caspase-8–mediated
cleavage of BID, a BH3-only Bcl-2 family member (13). The
activated and truncated BID (tBID) then engages the intrinsic
pathway for efficient apoptosis induction (13). NSAIDs rely on
the intrinsic pathway to kill CRC cells (14, 15). Nonetheless, it is
still unclear whether apoptosis induction is essential for the an-
titumor activities of NSAIDs.
In this study, we found that NSAID treatment activates BID
and the extrinsic apoptotic pathway in human intestinal adeno-
mas. Loss of BID almost completely abolishes NSAID-mediated
tumor suppression and killing of oncogenic intestinal stem cells
in APC-deficient mice. BID is activated by a synthetic lethal
interaction and mediates the effects of NSAIDs through cross-
talk between the extrinsic and intrinsic pathways. Our results
indicate that BID-dependent killing of tumor-initiating stem
cells is critical for cancer prevention by NSAIDs.
Results
NSAIDs Activate Caspase 8 and BID in Human Colonic Adenomas. To
determine the role of the extrinsic apoptotic pathway in NSAID-
mediated tumor suppression, we used terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) and active caspase
8 staining to analyze advanced colonic adenomas from patients
taking aspirin or other NSAIDs and control samples from
patients without NSAID use (16). The number of TUNEL-pos-
itive cells in the adenomas of the NSAID-treated patients was
5.0-fold higher compared with those in the control group (Fig.
1A). Active caspase 8 positive cells were markedly increased in
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the patients taking NSAIDs (Fig. 1B), and detected in 8 of 9
adenomas from NSAID users, but only in 1 of 7 from nonusers.
Upon analyzing olfactomedin 4 (OLFM4) (Fig. 1C, Left), which
marks human crypt base columnar cells (CBCs), representing
active intestinal stem cells (ISCs) (17), we found active caspase
8/OLFM4 double-positive cells were significantly increased by
more than 12-fold in the adenomas from NSAID takers com-
pared with nonusers (Fig. 1C, Right). Most notably, BID cleavage
was detected in several adenomas with high BID expression from
NSAID users, but not in any adenomas from the patients not
taking NSAIDs (Fig. 1D). These results suggest that NSAIDs kill
oncogenic stem cells in human adenomas, and activation of the
DR pathway and BID may contribute to this effect of NSAIDs.
BID Is Required for Tumor Suppression by NSAIDs in APCMin/+ Mice.
To determine whether BID is required for the chemopreventive
effects of NSAIDs, we crossed APCMin/+mice, a genetic model of
intestinal adenomas (18), with BID KO mice (19) and generated
age- and sex-matched cohorts of C57BL/6J APCMin/+ mice with
different BID genotypes. These mice were then fed an AIN-93G
diet containing 0 (control) or 200 ppm sulindac, and analyzed
for intestinal polyp formation. Sulindac treatment suppressed
small intestinal adenoma formation in BID+/+/APCMin/+ mice
by more than 80% compared with the untreated mice (Fig. 2
A–C). Remarkably, this effect of sulindac was almost com-
pletely lost in BID−/−/APCMin/+ mice, in which the number of
small intestinal polyps was only slightly reduced (Fig. 2C).
Sulindac was also less effective in the small intestine of BID
heterozygous APCMin/+ mice (Fig. 2C). Similar observations
were made in the colon of APCMin/+ mice (Fig. 2 A–C).
Indomethacin (10 ppm), also an NSAID with antitumor activity
(15), was similarly BID-dependent in reducing small intestinal
adenoma formation (Fig. S1). In untreated animals, loss of BID
did not significantly affect the size and number of small in-
testinal polyps, but led to an increase in polyp number in the
colon of APCMin/+ mice (Fig. 2C).
We then compared the effects of prolonged sulindac treat-
ment on the survival of BID+/+ and BID−/− APCMin/+ mice. In
striking contrast to BID+/+/APCMin/+ mice (n = 9), which were
alive after 70 wk of treatment, all of the BID−/−/APCMin/+ mice
(n = 11) died before 35 wk, surviving only slightly longer than
those on the control diet (∼30 wk) (Fig. 2D). The difference
between the BID+/+ and BID−/− groups is highly significant (70
vs. 33 wk, P = 0.0005) (Fig. 2D). Together, these results dem-
onstrate that BID plays an essential role in NSAID-mediated
chemoprevention in APCMin/+ mice.
BID Is Required for NSAID-Induced Killing of Intestinal Stem Cells in
APCMin/+ Mice. We investigated how BID mediates the chemo-
preventive effects of NSAIDs in APCMin/+ mice. We found that
crypt cell apoptosis detected by TUNEL and active caspase 3
staining was significantly reduced in the small intestine and
colon of sulindac- or indomethacin-treated BID−/−/APCMin/+
mice relative to BID+/+/APCMin/+ mice (Fig. 3 A and B and Fig.
S2 A and B). In contrast, activation of caspase 8 by sulindac or
indomethacin was not affected by the absence of BID (Fig.
S2C). Sulindac was shown to preferentially kill ISCs in the crypt
bottom of APCMin/+ mice (16), which can be detected by
markers such as Lgr5 and OLFM4 (20). Analysis of Lgr5-
EGFP–marked mice revealed that the killing effect of sulindac
and indomethacin on ISCs indicated by TUNEL/EGFP double-
positive staining was reduced in the small intestine and colon of
BID−/−/APCMin/+ mice relative to BID+/+/APCMin/+ mice (Fig.
3C and Fig. S2D). Using OLFM4 RNA in situ hybridization to
detect CBCs, we found the killing effect of sulindac and in-
domethacin on ISCs indicated by TUNEL/OLFM4 double-
positive staining was also reduced in the small intestine of
BID−/−/APCMin/+ mice (Fig. S2E). Inhibition of cyclooxygenase
2 (COX 2) by NSAIDs has been implicated as a mechanism
of NSAID-mediated chemoprevention (21). Sulindac and
indomethacin treatment reduced plasma prostaglandin E2
metabolites (PGEM) by ∼50% in BID+/+/APCMin/+, but these
effects were intact in BID−/−/APCMin/+ mice (Fig. S2F), sug-
gesting that BID functions downstream of COX 2 inhibition in
suppressing tumorigenesis. Together, these results indicate that
BID mediates the chemopreventive effects of NSAIDs through
selective killing of APC-deficient ISCs.
BID Mediates NSAID-Induced Apoptosis Through the Mitochondrial
Pathway. To further delineate the functional role of BID in
NSAID-mediated tumor suppression, we analyzed HCT116 co-
lon cancer cells, which contain a β-catenin–activating mutation and
can recapitulate the anticancer and apoptotic effects of NSAIDs
in mice (14–16). We generated BID knockout (BID KO) HCT116
cells by using homologous recombination (Fig. S3 and Fig. 4A)
and compared WT and BID KO cells for their responses to
NSAIDs and other anticancer agents. Strikingly, apoptosis in-
duced by sulindac and indomethacin, as determined by nuclear
fragmentation and annexin V staining, was almost completely
blocked in BID KO cells (Fig. 4B and Fig. S4A). BID deficiency
abrogated NSAID-induced Bax multimerization (Fig. 4C), mito-
chondrial membrane depolarization (Fig. 4D), cytosolic release of
cytochrome c and SMAC (Fig. 4E), and activation of caspases 9, 7,
and 3 (Fig. 4F). Reconstituting BID expression in BID KO cells
Fig. 1. NSAID treatment activates caspase 8 and BID in human advanced
adenomas. (A–C) Advanced adenomas from nine patients taking NSAIDs and
seven patients not taking NSAIDs were analyzed by TUNEL staining (green)
(A), active caspase 8 (Casp 8) staining (red) (B), and OLFM4 (green) and active
caspase 8 (red) double staining (C ). (Left) Representative staining pic-
tures. (Right) Mean numbers + SD of positive cells per field. (Scale bars:
25 μm.) ***P < 0.001. Arrows indicate example positive cells. (D) BID
expression in the adenomas was analyzed by Western blotting using
homogenized tissue lysates. Each lane represents an individual patient.
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restored sulindac-induced apoptosis (Fig. S4B). In contrast to
wild-type (WT) cells, the long-term survival of BID KO cells, as
analyzed by colony formation assay, did not decrease following
NSAID treatment (Fig. S4C).
NSAIDs also required BID to induce apoptosis in other CRC
cell lines, including APC-mutant DLD1 and HT29 cells, and
APC-WT RKO cells (Fig. S4D). Furthermore, BID-dependent
apoptosis was induced by other NSAIDs, including sulindac
sulfone, a sulindac derivative (22), and SC236, a COX 2-specific
inhibitor structurally unrelated to sulindac and indomethacin
(23) (Fig. S5 A–C). In contrast, BID deficiency did not affect
apoptosis induced by staurosporine, camptothecin, or over-
expression of the BH3-only protein PUMA, but attenuated ap-
optosis induced by tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) (Fig. S5D). These results demonstrate
a prominent and specific role of BID in mediating the anticancer
and apoptotic effects of NSAIDs.
BID Is Activated by NSAIDs Through the Extrinsic Apoptotic Pathway.
We determined how NSAIDs activate BID to engage the mito-
chondrial pathway to kill colon cancer cells. tBID was observed
in HCT116 cells treated with different NSAIDs (Fig. 5A and Fig.
S5 A and B) and could be detected as early as 18 h after treat-
ment (Fig. 5A). The short form of DR5, but not DR4, was in-
duced by NSAIDs in WT and BID KO HCT116 cells (Fig. 5B
and Fig. S6 A and B). The induction of DR5 by NSAIDs was
independent of p53 (Fig. S6C), which can activate DR5 following
DNA damage (24), and observed in different CRC cells (Fig.
S6D). The short form of c-FLIP (FLIPs), a negative regulator of
caspase 8 activation, was markedly down-regulated before BID
Fig. 2. BID is required for tumor suppression by NSAIDs in APCMin/+mice. Age- and sex-matched APCMin/+mice with different BID genotypes were fed control
or NSAID-containing AIN93G diet. (A) Representative images of small intestine and colon from BID+/+ and BID−/−APCMin/+mice treated with sulindac (200 ppm) for 4
mo, with arrows indicating visible macroadenomas. (B) Representative images of small intestine and colon of control mice and mice treated with sulindac (200 ppm)
for 2 mo, with arrows indicating microscopic lesions. (C) Mean numbers + SD of small intestinal and colonic adenomas (≥0.5 mm in diameter) in BID+/+, BID+/−, and
BID−/− APCMin/+mice treated ± sulindac as in B. *P < 0.05; **P < 0.01; ***P < 0.001 (n = 4 per group). (D) Kaplan–Meier survival curves of BID+/+ and BID−/− APCMin/+
mice treated ± sulindac (200 ppm) for 70 wk. BID+/+ vs. BID−/− APCMin/+ mice, P = 0.0005 (log-rank test). (Scale bars: A, 1 cm; B, 2 mm.)
Fig. 3. BID deficiency abolishes NSAID-induced apoptosis in intestinal stem cells in APCMin/+mice. (A and B) BID+/+ and BID−/− APC Min/+mice were fed control
(CT) or experimental AIN93G diet containing 200 ppm sulindac (SUL) or 10 ppm indomethacin (INDO) for 1 wk. Small intestinal and colonic sections were
analyzed for apoptosis by TUNEL staining (green) (A) and active caspase 3 staining (brown) (B). (Upper) Representative staining pictures of small intestinal
sections, with arrows indicating example cells with positive staining. (Lower) Mean + SD of positive signals in the small intestinal and colonic crypts. (C) Lgr5-
EGFP–marked BID+/+ and BID−/− APCMin/+ mice were treated as in A and analyzed for intestinal stem cell apoptosis by TUNEL (green) and EGFP (Lgr5; red)
double staining. (Upper) Representative staining pictures of small intestinal sections, with arrows indicating example double-positive cells. (Lower) Mean + SD
of TUNEL/Lgr5 double-positive signals in the small intestinal and colonic crypts. (Scale bars: 25 μm.) *P < 0.05; **P < 0.01; ***P < 0.001 (n = 3 per group).
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cleavage in NSAID-treated colon cancer cells (Fig. 5B and Fig.
S6D). Similar to the finding in mice (Fig. S2C), caspase 8 acti-
vation was found in NSAID-treated BID KO cells (Fig. 4F),
suggesting activation of BID through the extrinsic pathway. We
therefore tested this possibility by perturbing the extrinsic
pathway components. BID cleavage in sulindac-treated HCT116
cells was suppressed by transient knockdown of DR5 or stable
knockdown of caspase 8 (Fig. 5 C and D). Sulindac-induced
apoptosis was blocked by stable knockdown of caspase 8 (Fig.
5D) and partially inhibited by transient knockdown of DR5 or
expression of dominant negative FADD (Fig. 5C and Fig. S6E),
which is likely due to incomplete inhibition of DR5 expression
and FADD activity. Together, these results demonstrate that
BID is activated by NSAIDs through the extrinsic pathway and
mediates apoptosis induction by engaging the intrinsic pathway
to amplify the apoptotic signal.
NSAID-Induced DR Signaling Triggers BID-Dependent Synthetic
Lethality in APC-Deficient Cells with c-Myc Activation. The antican-
cer effect of NSAIDs depends on selective killing of neoplastic
cells (25). To determine this selectivity, we analyzed NCM356
normal intestinal epithelial cells (IECs), which have normal epi-
thelial morphology and a functional APC pathway (26). NCM356
cells were resistant to NSAIDs and lacked BID cleavage, Bax
multimerization, and caspases 8 and 3 activation, but remained
sensitive to camptothecin and staurosporine (Fig. 5 E and F and
Fig. S6F). Surprisingly, DR5 induction and FLIPs down-regulation
were still observed in NCM356 cells following NSAID treatment
(Fig. 5E). In both HCT116 and NCM356 cells, NSAID treatment
similarly modulated the transcription and mRNA expression of
the proximal DR pathway components, including DR5, c-FLIP,
and the decoy receptors DcR1 and DcR3 (Fig. S7 A–D). Lack of
apoptotic response even with DR pathway modulation was veri-
fied in another colon-derived and normal cell line, CRL-1831 (Fig.
S7 E and F). Therefore, activation of the DR pathway by NSAIDs
can occur in normal cells up to a point before caspase 8 and
BID cleavage.
We then probed the selective activation of BID and caspase 8
by NSAIDs in neoplastic cells considering factors present in
neoplastic cells but not normal cells. Loss of APC drives in-
testinal tumorigenesis by activating c-Myc (27, 28), which can
Fig. 4. BID mediates NSAID-induced apoptosis in CRC cells through the
mitochondrial pathway. (A) Western blot of BID in WT and two independent
clones of BID knockout (BID KO) HCT116 cell lines. (B) Apoptosis at indicated
time points in WT and BID KO HCT116 cells treated with 120 μM sulindac
sulfide or 500 μM indomethacin was analyzed by counting cells with con-
densed and fragmented nuclei. Results were expressed as means + SD of
three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. (C) BAX
and BAK multimerization was analyzed by cross-linking the mitochondrial
fractions isolated from cells treated as in B for 36 h, followed by SDS/PAGE
under nonreducing conditions and Western blotting. Cox IV, a mitochondrial
protein, was used as a control for loading and fractionation. (D) Mitochon-
drial membrane potential in cells untreated (UN) or treated with sulindac
sulfide (SUL) or indomethacin (INDO) as in B for 48 h was analyzed by Mito-
Tracker Red staining followed by flow cytometry. (E) Cytochrome c (Cyto c)
and SMAC/DIABLO release were analyzed by Western blotting of cytosolic
fractions isolated from cells treated with sulindac sulfide as in C. α-Tubulin,
a cytosolic protein, was used as control for loading and fractionation. (F)
Western blot of caspase (Casp) activation at the indicated time points in cells
treated as in B. Arrowheads indicate caspase cleavage fragments.
Fig. 5. BID is specifically activated by NSAIDs in cancer cells through the
death receptor pathway. (A) Western blots of HCT116 cells treated with 120
μM sulindac sulfide or 500 μM indomethacin, with the arrowhead indicating
tBID. (B) HCT116 cells were treated as in A, and analyzed for DR4, DR5, and
FLIPs expression at indicated time points by Western blotting. (C) HCT116
cells were transfected with control scrambled or DR5 siRNA, and then trea-
ted with sulindac sulfide as in A. (Upper) Western blot analysis of indicated
proteins at 36 h after treatment. (Lower) Apoptosis was analyzed by counting
condensed/fragmented nuclei after nuclear staining at 24 h after treatment. (D)
Parental and stable caspase 8 knockdown (Casp 8 KD) HCT116 cells were treated
with sulindac sulfide as in A. (Upper) Western blot analysis of indicated proteins
at 24 h after treatment. (Lower) Apoptosis was analyzed as in C at 24 h after
treatment. (E) Indicated proteins were analyzed byWestern blotting in NCM356
cells treated with sulindac sulfide as in A for 36 h. (F) BAX multimerization in
NCM356 and HCT116 cells was analyzed as in Fig. 4C. Results in C and D were
expressed as means + SD of three independent experiments. ***P < 0.001.
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trigger a synthetic lethal interaction in normal and tumor cells
with high levels of DR5 (29). We therefore tested whether either
APC loss or c-Myc activation sensitizes IECs to NSAIDs in an
otherwise normal background. Knockdown of APC by siRNA, in
conjunction with sulindac treatment, resulted in caspase 8 and
BID cleavage, apoptosis induction, caspase 3 activation, loss of
viability, and enhanced DR5 induction and FLIPs down-regula-
tion in NCM356 cells (Fig. 6 A and B and Fig. S8 A and E). The
killing effects of APC depletion require DR5, BID, and FLIPs
depletion, as knockdown of DR5 or BID, or transfection of
FLIPS suppressed apoptosis and restored cell viability in APC-
depleted and NSAID-treated NCM356 cells (Fig. S8 B–E and
Fig. 6B). Conversely, c-FLIP knockdown or DR5 transfection
phenocopied APC depletion in inducing apoptosis, loss of cell
viability, and caspase 8 and BID cleavage in NSAID-treated
NCM356 cells (Fig. 6 C and D and Fig. S8E).
As expected, APC depletion led to c-Myc induction in
NCM356 cells (Fig. 6A), and knockdown of c-Myc substantially
decreased caspase 8 activation, and abolished BID cleavage,
apoptosis, and loss of cell viability induced by APC deletion and
sulindac treatment (Fig. 6 A and B and Fig. S8E). Transfection of
c-Myc, but not a control vector, induced apoptosis in NSAID-
treated NCM356 cells (Fig. 6E and Fig. S8 F and G). Consis-
tent with the notion that c-Myc modulates the DR pathway
(29), c-Myc transfection further down-regulated FLIPS protein,
mRNA, and promoter activity and enhanced the expression of
DR5, DR4, and DcR2 in sulindac-treated NCM356 cells (Figs.
S8G and S9). The effects of c-Myc on apoptosis and cell viability
also depended on BID and DR5 and were inhibited by FLIPS
(Fig. 6E and Fig. S8F). These results demonstrate that APC
deficiency and subsequent c-Myc activation interact with NSAID-
induced DR signaling, leading to caspase 8 and BID cleavage and
selective killing of APC-deficient IECs.
Discussion
Despite the well-defined precursor lesions and genetic changes
in colorectal tumorigenesis (2), how NSAIDs inhibit this process
has remained obscure. Our results demonstrate that activation of
BID through the extrinsic pathway plays a vital role in NSAID-
mediated chemoprevention. It is possible that the adenomas with
high levels of BID and/or caspase 8 activity are less likely to
recur, compared with those with relatively low levels. Long-term
NSAID use is associated with a variety of side effects, such as
gastrointestinal, renal, and cardiovascular toxicities (25). It is
conceivable that the side effects of NSAIDs can be mitigated by
selectively enhancing NSAID-induced apoptotic signaling, or by
combining other agents with NSAIDs at lower and well-tolerated
doses to achieve safer and more effective cancer prevention (30).
BID largely accounts for the antitumor and apoptotic effects
of NSAIDs in APCMin/+mice, a classical model that recapitulates
the chemopreventive effects of NSAIDs in humans (7). The
general role of BID and the extrinsic pathway in chemo-
prevention needs to be verified by using carcinogen tumor
models and other genetically engineered mice. The increased
polyp number in the colon, but not in the small intestine of
BID-deficient APCMin/+ mice, suggests that a BID-mediated
effect is more engaged in colonic epithelial cells and con-
tributes to relatively lower tumor incidence in the colon of
APCMin/+ mice. It may reflect differences in apoptosis and
expression of other Bcl-2 family members in normal epithelial
cells of small intestine and colon (31). ISCs with regenerative
capability can sustain driver mutations and are likely to be the
most relevant cell target of NSAIDs in chemoprevention.
Tumor-initiating ISCs are likely to be more vulnerable to
apoptosis relative to normal ISCs because of c-Myc activation
by APC loss (32, 33), and compared with differentiated cells
on account of intrinsic high levels of c-Myc in ISCs (34). In
addition to their effects on colorectal tumorigenesis, NSAIDs
have been shown to be useful in treating precancerous lesions
of other tissues, and in adjuvant therapy for treating a variety
of cancers (25). It is possible that these effects of NSAIDs are
also mediated by BID through the DR pathway. Compared
with other anticancer drugs, NSAIDs seem to be more reliant
on BID to kill tumor cells, which is likely because BID is the
major, if not the only, BH3-only Bcl-2 family protein activated
by NSAIDs. In contrast, other drugs such as DNA-damaging
agents modulate multiple BH3-only proteins, including BID,
PUMA, Noxa, and BIM.
Suppression of intestinal tumorigenesis by NSAIDs seems to
be mediated by the BID-dependent synthetic lethal interaction
Fig. 6. APC depletion or c-Myc induction triggers BID activation and BID-
dependent apoptosis in NSAID-treated normal colonic epithelial cells. (A)
NCM356 normal colonic epithelial cells were transfected with the indicated
siRNA and then treated with 120 μM sulindac sulfide for 48 h. Indicated
proteins were analyzed by Western blotting. C Casp 3, cleaved caspase 3. (B)
NCM356 cells were transfected with indicated siRNA or siRNA/plasmid combi-
nations, and then treated with 120 μM sulindac sulfide for 48 h. Apoptosis was
measured by counting apoptotic nuclei after nuclear staining. (C and D) Western
blotting of the indicated proteins in NCM356 cells transfected as indicated,
and then treated with 120 μM sulindac sulfide for 36 h. (E) Apoptosis in
NCM356 cells transfected as indicated and treated with 120 μM sulindac sulfide
for 24 h was measured as in B. (F) A model of NSAID-mediated apoptosis in
APC-deficient cells. Results in B and E were expressed as means + SD of three
independent experiments. **P < 0.01; ***P < 0.001; N.S., not significant.
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of DR signaling and aberrant Wnt signaling, which can be caused
by inherited or sporadic APC mutations, activating β-catenin
mutations, or other alterations (2). NSAIDs do not discriminate
between cancer and normal cells in modulating the expression of
DR5, c-FLIP, and other DR family members, which is in-
sufficient for cell death. However, these changes in conjunction
with activation of Wnt signaling and ensuing c-Myc induction are
both sufficient and required to trigger caspase 8 and BID
cleavage, leading to apoptosis induction in an otherwise normal
background. Therefore, premalignant cells with APC loss and
aberrant Wnt signaling are primed for apoptosis due to c-Myc–
induced DR signaling, and the enhanced DR signaling by NSAIDs
helps reach a critical threshold for caspase 8 activation (Fig. 6F).
NSAIDs induce a number of apical signaling events (21), some of
which, such as endoplasmic reticulum (ER) stress, can trigger DR
signaling (35). Studying these signaling events may help identify
the direct target of NSAIDs in chemoprevention, which should
be an important area of future investigation. Exploiting synthetic
lethal interactions has been recognized as a powerful targeting
strategy (36) and may hold the key for developing effective pre-
ventive agents for other cancer types with defined gatekeeper or
driver mutations.
Materials and Methods
Analysis of Human Colonic Polyps. Frozen specimens from patients with
sporadic colonic adenomas, including nine patients treated with NSAIDs and
seven untreated patients, were acquired from theHealth Sciences Tissue Bank
of the University of Pittsburgh. Acquisition of the tissue samples was ap-
proved by the Institutional Review Board. Informed consent was received
from all participating patients. TUNEL and the intestinal stem cell marker
OLFM4 were analyzed by immunostaining of paraffin-embedded tissue as
described (16). Active caspase 8 staining was performed as described in SI
Materials and Methods.
Mice and Treatment. The procedures for all animal experiments were ap-
proved by the Institutional Animal Care and Use Committee of the Uni-
versity of Pittsburgh. C57BL/6J BID−/− (BID KO) mice, which were described
(19), were crossed with APCMin/+ mice (Jackson Laboratory) to generate
APCMin/+ mice with different BID genotypes. Lgr5-EGFP–marked BID+/+ and
BID−/− APCMin/+ mice were generated as described in SI Materials and
Methods. For NSAID treatment, 4-wk-old mice were fed AIN-93G diets
(Dyets) with or without 200 ppm sulindac (Sigma) or 10 ppm indomethacin
(Sigma) for 1 wk for apoptosis analysis, or for 2 or 4 mo for tumor phe-
notype analysis. Following treatment and killing of mice, analysis of ade-
noma numbers and apoptosis in adenoma tissues was done as described in
SI Materials and Methods. For survival analysis, BID+/+ and BID−/− APCMin/+
mice were fed sulindac or control diet for up to 70 wk when all mice
were killed.
Analysis of NSAID-Induced and BID-Mediated Apoptosis in Human CRC Cell
Lines and NCM356 Cells. Human CRC cell lines, including HCT116, HT29,
RKO, DLD1 and their derivatives, and NCM356 cells (Incell) (26), were treated
by NSAIDs and analyzed for apoptosis by nuclear staining, annexin V/pro-
pidium iodide staining, colony formation, mitochondrial membrane in-
tegrity, cytochrome c release, and Bax conformational change as described
in SI Materials and Methods.
Statistical Analysis. Statistical analyses were performed by using GraphPad
Prism IV software. Differences were considered significant if the probability
of the difference occurring by chance was less than 5 in 100 (P < 0.05).
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